| Literature DB >> 35221680 |
Harleen Kaur Rai1, Justine Schneider2, Martin Orrell3.
Abstract
BACKGROUND: There is a lack of digital resources that support the cognition and quality of life (QoL) of people with dementia. The individual cognitive stimulation therapy application (iCST app) aims to provide cognitive stimulation and social interaction to people with dementia and carers through interactive touch-screen technology. This study set out to determine the feasibility of conducting a full-scale, randomized controlled trial (RCT) with the iCST app.Entities:
Keywords: application; cognitive stimulation; feasibility trial; touch-screen
Mesh:
Year: 2021 PMID: 35221680 PMCID: PMC8866989 DOI: 10.2147/CIA.S323994
Source DB: PubMed Journal: Clin Interv Aging ISSN: 1176-9092 Impact factor: 4.458
Figure 1CONSORT flow diagram: participant flow through feasibility trial. *One dyad who did not receive the intervention in the experimental group was subsequently withdrawn from the study.
Demographics of People with Dementia and Carers.
| Total (n = 61) | iCST App (n = 31) | TAU (n = 30) | Tests for Homogeneity – p value | |
|---|---|---|---|---|
| Age in years: mean, SD | 73, 7.67 (range: 50–89) | 74.03, 6.83 | 71.81, 8.52 | 0.16 |
| Male (%) | 42 (69) | 22 (71) | 20 (67) | 0.72 |
| Ethnicity white (%) | 59 (97) | 29 (93.5) | 30 (100) | 0.37 |
| Relationship with carer: married (%) | 51 (84) | 27 (87) | 24 (80) | 0.39 |
| Lives with spouse/partner (%) | 52 (85) | 27 (87) | 25 (83) | 0.94 |
| Educationa: no qualifications or School Leaver O-Levels/GCE (%) | 25 (41) | 15 (48) | 10 (33) | 0.51 |
| Taking AchEI medication (%) | 43 (70.5) | 22 (71) | 21 (70) | 0.89 |
| Experience with technology: quite a lot or more | 13 (22) | 9 (29) | 4 (13) | 0.08 |
| Age in years: mean, SD | 66.89, 10.72 (range: 27–83) | 68.52, 8.96 | 65.15, 12.28 | 0.15 |
| Female (%) | 47 (77) | 26 (84) | 21 (70) | 0.20 |
| Ethnicity white (%) | 60 (98) | 31 (100) | 29 (97) | n/ab |
| Educationa: School Leaver O- Levels/GCE or Higher Education (BSc/BA) (%) | 33 (54) | 17 (55) | 16 (53) | 0.63 |
| Experience with technology: quite a lot or more (%) | 21 (35) | 10 (33) | 11 (37) | 0.65 |
Notes: aEducation categories included no qualifications, school leaver – O levels/GCE, school lever – A levels, higher education (BSc/BA), postgraduate education (MSc/MA/PhD), and other. bAll carers were white British with one missing value in the control group. Hence, no variation detected between the two groups.
Adjusted Means for Outcome Measures for People with Dementia and Carers in the iCST App and TAU Control Group at FU1
| FU1 | iCST App | TAU | MD | Difference CI (95%) | Effect Size (SMD) | p value |
|---|---|---|---|---|---|---|
| ADAS-Cog | 16.58 | 17.94 | −1.36 | −3.71 to 1.00 | 0.15 | 0.253 |
| QoL-AD | 37.92 | 34.80 | 3.12 | −0.48 to 6.73 | 0.40 | 0.088 |
| CSDD | 4.95 | 4.93 | 0.02 | −1.46 to 1.51 | 0.00 | 0.972 |
| EQ-5D | 80.12 | 73.12 | 7.00 | −2.07 to 16.06 | 0.37 | 0.127 |
| QCPR | 58.68 | 58.77 | −0.09 | −2.44 to 2.25 | 0.01 | 0.938 |
| QoL-AD [P] | 34.39 | 34.77 | −0.38 | −2.35 to 1.59 | 0.07 | 0.703 |
| CSDD [P] | 4.91 | 4.02 | 0.89 | −0.74 to 2.53 | 0.27 | 0.278 |
| BADLS [P] | 9.55 | 9.55 | 0.00 | −2.04 to 2.05 | 0.00 | 0.996 |
| NPI total [P] | 12.76 | 12.29 | 0.47 | −4.74 to 5.66 | 0.03 | 0.859 |
| EQ-5D | 88.71 | 85.22 | 3.49 | −1.61 to 8.57 | 0.29 | 0.176 |
| HADS-Anxiety | 5.36 | 5.03 | 0.33 | −1.05 to 1.71 | 0.08 | 0.634 |
| HADS-Depression | 2.56 | 3.18 | −0.62 | −1.70 to 0.47 | 0.18 | 0.257 |
| QCPR | 56.05 | 58.07 | −2.02 | −5.40 to 1.37 | 0.25 | 0.236 |
Abbreviations: MD, mean difference; CI, confidence interval; SMD, standardised mean difference; [P], proxy rated measure.
Adjusted Means for Outcome Measures for People with Dementia and Carers in the iCST App and TAU Control Group at FU2
| FU2 | iCST App | TAU | MD | Difference CI (95%) | Effect Size (SMD) | p value |
|---|---|---|---|---|---|---|
| ADAS-Cog | 17.00 | 17.48 | −0.48 | −3.37 to 2.40 | 0.05 | 0.735 |
| QoL-AD | 38.20 | 36.50 | 1.70 | −0.45 to 3.86 | 0.28 | 0.119 |
| CSDD | 4.94 | 4.87 | 0.07 | −1.76 to 1.92 | 0.01 | 0.933 |
| EQ-5D | 77.83 | 77.97 | −0.14 | −8.61 to 8.33 | 0.01 | 0.974 |
| QCPR | 58.05 | 58.88 | −0.83 | −3.76 to 2.11 | 0.11 | 0.574 |
| QoL-AD [P] | 33.25 | 33.13 | 0.12 | −2.36 to 2.61 | 0.02 | 0.921 |
| CSDD [P] | 5.86 | 5.03 | 0.83 | −1.35 to 3.01 | 0.18 | 0.446 |
| BADLS [P] | 9.57 | 10.58 | −1.01 | −3.04 to 1.03 | 0.13 | 0.324 |
| NPI total [P] | 11.86 | 10.91 | 0.95 | −4.69 to 6.60 | 0.07 | 0.736 |
| EQ-5Da | 86.58 | 78.89 | 7.69 | 2.32 to 13.06 | 0.53 | 0.006 |
| HADS-Anxiety | 5.28 | 5.72 | −0.44 | −2.04 to 1.15 | 0.09 | 0.575 |
| HADS-Depression | 3.28 | 3.14 | 0.14 | −0.95 to 1.23 | 0.04 | 0.798 |
| QCPR | 57.42 | 57.40 | 0.02 | −2.93 to 2.97 | 0.00 | 0.990 |
Note: aSignificant result at p < 0.05.
Abbreviations: MD, mean difference; CI, confidence interval; SMD, standardised mean difference; [P], proxy rated measure.
ACCEPT for a Full-Scale RCT with the iCST App41
| Component of Trial | Monitoring Methods | Amend? | Outcomes | |
|---|---|---|---|---|
| Trial design | Reviewed suitability of and adherence to research protocol. | No | Trial design and related components are appropriate. | |
| Sample size | Tested assumptions within protocol on: number of sites; recruitment rates; retention rates; and SD of primary outcomes. | Yes | Revision necessary in terms of sample size calculation; recruiting capacity; trial period; and funding. | |
| Interventions | Clinical governance | Assessed compliance with formal training in intervention through contact with local PIs. | Yes | Enhance formal training and supervision of local researchers and/or research nurses at each site eg, by additional training visits and/or catch-ups. |
| Intervention fidelity | Measured & assessed adherence to intervention through weekly telephone calls and analytics. | Yes | Enhance supervision of intervention using identifiable analytics. Extend the iCST app with more relevant activities and provide more guidance in its use eg, through the involvement of a formal carer. | |
| Participants | Recruitment strategy | Assessed participant flow per recruitment source. | Yes | Refine recruitment strategy eg, by promoting engagement within recruitment sources (eg, memory clinics) and include other sources such as the Alzheimer’s Society. |
| Eligibility criteria | Assessed reasons for ineligible participants and any barriers to recruitment. | Yes | Refine eligibility criteria eg, by making the iCST app compatible with a maximum number of devices. | |
| Consent procedures | Participant information sheets (PIS) | Monitored PIS distribution and emergence of questions related to the PIS through contact with PIs at local site. | No | PIS are appropriate. |
| Taking informed consent | Monitored consent documentation and appropriateness of forms through contact with PIs at local site. | No | Consent process and accompanying forms are appropriate. | |
| Randomisation process | Checked randomisation procedures including use of Sealed Envelope, randomisation sequences and accessibility by researchers. | No | Randomisation procedure and training of research team are appropriate. | |
| Blinding | Checked occurrences of unblinding by participants and whether unblinded researchers can keep other researchers blind. | Yes | Extend blinding procedures, eg, by checking whether blinded assessors can predict individual allocations. | |
| Data | Data collection | Assessed adherence to assessments and weekly telephone calls/questionnaires. | Yes | Refine schedules to reduce assessment burden and modify outcome measure selection. Enhance training of research team in data collection tools such as outcome measures to minimise errors and missing data. |
| Data quality | Tested missing data procedures listed within the analysis plan. | Yes | Refine missing data procedures in case of assessments missing in full eg, through statistical analyses. | |
| Data management | Tested suitability of trial database, storage of data, related procedures and software. | Yes | Refine trial database and data monitoring procedures considering the amount of data in larger trial. | |
| Research Governance | Research protocol adherence | Tested adherence to research protocol as widely as possible through regular contact with local PIs. | Yes | Enable quality assurance officer (QAO) to test adherence as widely as possible. Refine protocol to enhance quality assurance plan and training of team. |
| Adverse events (AE) | Assessed occurrences and severity of AEs, and reporting procedures. | Yes | Refine AE reporting and assessment procedures through the addition of a QAO. | |
| Health & Safety (H&S) | Monitored H&S procedures, eg, during installation and assessment visits. | No | Refinement to H&S procedures not necessary. | |
| Data analysis | Tested an analysis plan on the obtained data. | Yes | Refine analysis plan to address research aims in full in terms of effectiveness on outcomes. | |
| Trial management | Reviewed role descriptions of research team including at local sites. | Yes | Extension of research team will be necessary through a Trial Steering Committee and a Data Monitoring Committee. Refine roles eg, depending on workloads. | |
Notes: Adapted from Charlesworth G, Burnell K, Hoe J et al. Acceptance checklist for clinical effectiveness pilot trials: a systematic approach. BMC Med Res Methodol 13, 78 (2013). Creative Commons Attribution License ()41.